CDTX News and Press, Cidara Therapeutics Inc. From 02/14/23

SAN DIEGO, Feb. 14, 2023 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed to help improve the standard of care for patients facing serious diseases, today announced that it has received formal notice from The Nasdaq...

SAN DIEGO and SHANGHAI, China, Feb. 01, 2023 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to improve the standard of care for patients facing serious diseases, and WuXi XDC, a leading global CRDMO company dedica...

Summary Today, we are putting the spotlight on small biotech concern Cidara Therapeutics for the first time in more than a year and a half. The company has an impressive set of collaboration deals with larger drug firms and its first FDA approval is on the near-term horizon. An inve...

%Biotechs have been absolutely hogging the headlines so far this week, and this afternoon appears to be a greater continuation of this theme. Earlier during Wednesday’s session, it was announced that a San Diego-based micro cap announced that the U.S. Food and Drug Administration (FDA) A...

Cidara Therapeutics ( NASDAQ: CDTX ) climbed ~17% pre-market Wednesday after the company announced that a group of experts at the FDA voted in favor of its antifungal therapy rezafungin. The agency's Antimicrobial Drugs Advisory Committee evaluated rezafungin as a treatment for ca...

FDA decision expected by PDUFA target action date of March 22, 2023 If approved, rezafungin will be the first new drug for the treatment of candidemia and invasive candidiasis in over a decade SAN DIEGO and PARSIPPANY, N.J., Jan. 25, 2023 (GLOBE NEWSWIRE) -- Cidara Therapeutics, I...

Cidara Therapeutics ( NASDAQ: CDTX ) edged higher Friday morning after the FDA posted briefing documents on rezafungin, an antifungal treatment the company develops in partnership with Melinta Therapeutics ( OTCPK:MLNTQ ) and Mundipharma Medical. In September, the FDA accepted the...

SAN DIEGO, Jan. 04, 2023 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to improve the standard of care for patients facing serious diseases, today announced that it has selected its first oncology drug-Fc conjuga...

SAN DIEGO, Dec. 01, 2022 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to improve the standard of care for patients facing serious diseases, today announced that the U.S. Patent and Trademark Office issued U.S. P...

SAN DIEGO, Nov. 29, 2022 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to improve the standard of care for patients facing serious diseases, today announced that Institutional Shareholder Services (ISS) and...